Clinical, Cosmetic and Investigational Dermatology (May 2025)
Successful Treatment of Severe Nail Lichen Planus with Janus Kinase 1 Inhibitor Abrocitinib
Abstract
Yingzhi Luo,1,* Jian Wu,2,* Xingyun Zhao,1,* Ping Yang,1 Yunmi Qiu,1 Liming Wu,1 Jianbo Zhong1 1Department of Dermatology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People’s Republic of China; 2Department of Pathology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jianbo Zhong, Department of Dermatology, Affiliated Hangzhou First People’s Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, People’s Republic of China, Tel +86 13858168189, Email [email protected]: Nail lichen planus (NLP) is a chronic inflammatory disease that presents a significant therapeutic challenge. It can progress rapidly, leading to impaired nail morphology and function. Currently, there is no established standard therapy due to limited efficacy or potential for significant adverse reactions. In this report, we present a case of very severe NLP successfully treated with the Janus kinase 1 (JAK1) inhibitor abrocitinib, with no associated discomfort.Keywords: nail lichen planus, Janus kinase 1 inhibitor, abrocitinib
